Real-world experience with foslevodopa/foscarbidopa in Germany: therapeutic insights and lessons learned
Patients with advanced Parkinson’s disease (PD) often need to continue with device-aided therapies (DAT), such as intestinal and subcutaneous infusion therapies. Recently, continuous subcutaneous administration of foslevodopa/foscarbidopa (LDp/CDp) has emerged as a new therapeutic method. Two years after its approval i...